Full Length Research Paper
References
|
Amouri I, Abbes S, Sellami H, Makni F, Sellami A, Ayadi A (2010). La candidose vulvovaginale : Revue. |
|
|
Arendrup MC (2013). Candida and candidaemia. Susceptibility and epidemiology. Danish Medical Journal 60:B4698. |
|
|
Arfiputri DS, Hidayati AN, Handayani S, Ervianti E (2018). Risk factors of Vulvovaginal Candidiasis in Dermato-Venerology outpatients clinic of Soetomo General Hospital, Surabaya, Indonesia. African Journal of Infectious Diseases 12:90-94. |
|
|
Auler M, Morreira D, Rodrigues FF, Abr-Ao MS, Margarido PF, Matsumoto FE (2010). Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Medical Mycology 48:211-216. |
|
|
Bernstein JA, Seidu L (2015). Chronic vulvovaginal Candida hypersensitivity: An underrecognized and undertreated disorder by allergists. Allergy and rhinology 6:e44-e49. |
|
|
Bonouman-Ira V, Angora E, Djohan V, Vanga-Bosson H, Sylla-ThanonK, Beourou S, Touré AO, Faye-Ketté H, Dosso M, Koné M (2011). Profil de résistance des Candida non albicans à Abidjan en 2011. Revue Bio-Africa 9:27-31. |
|
|
Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Martinez AM, Mendes JF, Meireles, MC, Xavier MO (2017). Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Brazilian Journal of Microbiology (BJM) official publication of the Sociedade Brasileira de Microbiologia 48:145-150. |
|
|
Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, Blasi N, Festa A (2003). An epidemiological survey of vulvovaginal candidiasis in Italy. European Journal of Obstetrics and Gynecology and Reproductive Biology 110:66-72. |
|
|
Crouss T, Sobel JD, Smith K, Nyirjesy P (2018). Long-Term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy. Journal of Lower Genital Tract Disease. |
|
|
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R (2018). Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet Infectious Diseases. |
|
|
Djohan V, Angora K., Vanga-Bosson A, Konaté A, Kassi F, Yavo W, Kiki-Barro P, Menan H, Koné M (2012). Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques à Abidjan (Côte d'Ivoire). Journal de Mycologie Médicale 22:129-133. |
|
|
Ekpenyong CE, Inyang-etoh EC, Ettebong EO, Akpan UP, Ibu JO, Daniel NE (2012). Recurrent vulvovaginal candidosis among young women in south eastern Nigeria: the role of lifestyle and health-care practices. International Journal of STD andAIDS 23:704-709. |
|
|
Fan S, Liu X, Wu C, Xu L, Li J (2015). Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia 179:95-101. |
|
|
Fidel P, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, Quayle AJ, Dunlap K (2004). An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopthogenesis of vulvovaginal candidiasis. Infection and Immunity 72:2939-2946. |
|
|
Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E (2006). Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. European Journal of Obstetrics and Gynecology and Reproductive Biology 126:121-125. |
|
|
Grinceviciene S, Ruban K, Bellen G, Donders GG (2018). Sexual behaviour and extra-genital colonisation in women treated for recurrent Candida vulvo-vaginitis. Mycoses. |
|
|
Hu Z, Zhou W, Yue XA, Mu LY, Jiang YM (2015). Dynamical evaluation of vaginal micro-ecosystem in a Chinese woman with recurrent vulvovaginal candidiasis. Genetics and Molecular Research 14:2626-2630. |
|
|
Khan M, Ahmed J, Gul A, Ikram A, Lalani FK (2018). Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infection and Drug Resistance 11:447-456. |
|
|
Konaté A, Yavo W, Kassi FK, Djohan V, Angora EK, Barro-Kiki PC, Bosson-Vanga H, Soro F, Menan EH (2014). Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan (Cote d'Ivoire). Journal de Mycologie Médicale 24:93-99. |
|
|
Panizo MM, Reviákina V, Dolande M, Selgrad S (2009). Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Medical Mycology 47:137-143. |
|
|
Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005). Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. Journal of Clinical Microbiology 43:2155-2162. |
|
|
Ringdahl EN (2000). Treatment of recurrent vulvovaginal candidiasis. American Family Physician 61:3306-3317. |
|
|
Rylander E, Berglund AL, Krassny C, Petrini B (2004). Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sexually Transmitted Infections 80:54-57. |
|
|
Shahid Z, Sobel JD (2009). Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagnostic Microbiology and Infectious Disease 64:354-356. |
|
|
Sobel J (2015). Recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology 15:714-716. |
|
|
Sobel JD (2007). Vulvovaginal candidosis. Lancet (London, England) 369:1961–1971. |
|
|
Sobel JD, Sobel R (2018). Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opinion on Pharmacotherapy 19:971-977. |
|
|
Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C, Horowitz B, Von Thron J, Edwards L, Panzer H, Chu TC (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. The New England Journal of Medicine 351:876-883. |
|
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
